FINWIRES · TerminalLIVE
FINWIRES

百乐嘉利宝股价暴跌15%,原因是中期销量下滑,2026财年盈利前景黯淡

-- 受需求疲软、北美供应中断以及市场产能过剩等因素影响,瑞士巧克力制造商百乐嘉利宝(Barry Callebaut,股票代码:BARN.SW)股价周四早盘下跌9%,原因是市场需求疲软、供应中断以及竞争激烈的产能过剩导致其中期销量和营业利润下滑,迫使该公司下调了2026财年的盈利预期。 截至2月28日的六个月,集团总销量同比下降6.9%至1,010,247吨,主要受不利市场因素影响。其中,全球巧克力销量下降5.1%,全球可可销量下降14.3%。最终,这家巧克力和可可制品公司的营收从去年同期的72.9亿瑞士法郎骤降至67.5亿瑞士法郎。 营业利润(息税前利润,EBIT)下滑2.2%至2.894亿瑞士法郎,经常性息税前利润下滑5.7%至3.109亿瑞士法郎。尽管如此,由于所得税支出减少,归属于巴里公司股东的净利润从去年的3210万瑞士法郎大幅增长至8940万瑞士法郎。此外,可可豆价格“大幅快速”下跌,加上公司采取运营措施减少营运资本,使得公司净债务从61.1亿瑞士法郎降至36亿瑞士法郎,从而降低了融资成本。 巴里公司计划优先恢复销量并引领市场重回增长轨道,因此上调了2026财年的销量预期,预计销量将下降1%至3%,而非1月21日预测的个位数百分比降幅。与此同时,巴里公司警告称,未来12个月以当地货币计算的经常性息税前利润(EBIT)将出现15%左右的萎缩,盈利前景可能受到中东地区动荡局势的影响。 此前,百乐嘉利宝预计经常性息税前利润(EBIT)将实现个位数低至中等增长,而以当地货币计算的经常性税前利润将实现两位数增长。在此背景下,公司指出,必须采取行动才能实现持续盈利增长。虽然具体细节将于6月公布,但百乐嘉利宝计划专注于关键市场和细分领域,重新打造清晰的高端品牌形象,并过渡到一支“规模更小、更注重商业运营”的领导团队。 “回顾我在百乐嘉利宝的头几个月,我们显然拥有无可比拟的市场地位、深厚的专业知识和巨大的增长潜力。与此同时,在经历了行业动荡和转型之后,我们还有大量工作要做,以重振公司。我们需要恢复基本面,提升服务水平,并赋能我们的区域业务,”首席执行官海因·舒马赫表示。

Related Articles

Asia

Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%

Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.

$KOSDAQ:440110
Asia

ASX Biggest Losers

Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07

$^AXJO$ASX:COH$ASX:EVT$ASX:NXG$ASX:ORG$ASX:PDN$ASX:RHC$ASX:SX2$ASX:TLX$ASX:TUA$ASX:WTC
Asia

Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal

Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.

$BOM:524715$NSE:SUNPHARMA